Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 397 to 404 of 404 entries
Sorted by: Best Match Show Resources per page
Garcinol from Garcinia indica inhibits HIV-1 reverse transcriptase-associated ribonuclease H.

Archiv der Pharmazie

Corona A, Seibt S, Schaller D, Schobert R, Volkamer A, Biersack B, Tramontano E.
PMID: 34008218
Arch Pharm (Weinheim). 2021 Sep;354(9):e2100123. doi: 10.1002/ardp.202100123. Epub 2021 May 18.

The bioactive components of Garcinia indica, garcinol (camboginol), and isogarcinol (cambogin), are suitable drug candidates for the treatment of various human diseases. HIV-1-RNase H assay was used to study the RNase H inhibition by garcinol and isogarcinol. Docking of...

Cite
Corona A, Seibt S, Schaller D, et al. Garcinol from Garcinia indica inhibits HIV-1 reverse transcriptase-associated ribonuclease H. Arch Pharm (Weinheim). 2021;354(9):e2100123doi: 10.1002/ardp.202100123.
Corona, A., Seibt, S., Schaller, D., Schobert, R., Volkamer, A., Biersack, B., & Tramontano, E. (2021). Garcinol from Garcinia indica inhibits HIV-1 reverse transcriptase-associated ribonuclease H. Archiv der Pharmazie, 354(9), e2100123. https://doi.org/10.1002/ardp.202100123
Corona, Angela, et al. "Garcinol from Garcinia indica inhibits HIV-1 reverse transcriptase-associated ribonuclease H." Archiv der Pharmazie vol. 354,9 (2021): e2100123. doi: https://doi.org/10.1002/ardp.202100123
Corona A, Seibt S, Schaller D, Schobert R, Volkamer A, Biersack B, Tramontano E. Garcinol from Garcinia indica inhibits HIV-1 reverse transcriptase-associated ribonuclease H. Arch Pharm (Weinheim). 2021 Sep;354(9):e2100123. doi: 10.1002/ardp.202100123. Epub 2021 May 18. PMID: 34008218.
Copy Download .nbib Format: NLM
Protective T cell receptor identification for orthotopic reprogramming of immunity in refractory virus infections.

Molecular therapy : the journal of the American Society of Gene Therapy

Stief TA, Kaeuferle T, Müller TR, Döring M, Jablonowski LM, Schober K, Feucht J, Dennehy KM, Willier S, Blaeschke F, Handgretinger R, Lang P, Busch DH, Feuchtinger T.
PMID: 34058386
Mol Ther. 2022 Jan 05;30(1):198-208. doi: 10.1016/j.ymthe.2021.05.021. Epub 2021 May 29.

Viral infections cause life-threatening disease in immunocompromised patients and especially following transplantation. T cell receptor (TCR) engineering redirects specificity and can bring significant progress to emerging adoptive T cell transfer (ACT) approaches. T cell epitopes are well described, although...

Cite
Stief TA, Kaeuferle T, Müller TR, et al. Protective T cell receptor identification for orthotopic reprogramming of immunity in refractory virus infections. Mol Ther. 2021;30(1):198-208doi: 10.1016/j.ymthe.2021.05.021.
Stief, T. A., Kaeuferle, T., Müller, T. R., Döring, M., Jablonowski, L. M., Schober, K., Feucht, J., Dennehy, K. M., Willier, S., Blaeschke, F., Handgretinger, R., Lang, P., Busch, D. H., & Feuchtinger, T. (2022). Protective T cell receptor identification for orthotopic reprogramming of immunity in refractory virus infections. Molecular therapy : the journal of the American Society of Gene Therapy, 30(1), 198-208. https://doi.org/10.1016/j.ymthe.2021.05.021
Stief, Tanja A, et al. "Protective T cell receptor identification for orthotopic reprogramming of immunity in refractory virus infections." Molecular therapy : the journal of the American Society of Gene Therapy vol. 30,1 (2022): 198-208. doi: https://doi.org/10.1016/j.ymthe.2021.05.021
Stief TA, Kaeuferle T, Müller TR, Döring M, Jablonowski LM, Schober K, Feucht J, Dennehy KM, Willier S, Blaeschke F, Handgretinger R, Lang P, Busch DH, Feuchtinger T. Protective T cell receptor identification for orthotopic reprogramming of immunity in refractory virus infections. Mol Ther. 2022 Jan 05;30(1):198-208. doi: 10.1016/j.ymthe.2021.05.021. Epub 2021 May 29. PMID: 34058386.
Copy Download .nbib Format: NLM
Heart failure with recovered ejection fraction (HFrecEF): A new entity with improved cardiac outcome.

Pacing and clinical electrophysiology : PACE

Zeller J, Hubauer U, Schober A, Schober A, Keyser A, Fredersdorf S, Uecer E, Maier LS, Jungbauer C.
PMID: 34687476
Pacing Clin Electrophysiol. 2021 Dec;44(12):2015-2023. doi: 10.1111/pace.14391. Epub 2021 Nov 04.

BACKGROUND: Aim of the study was a better characterization of heart failure (HF) with recovered ejection fraction (HFrecEF) and undulating EF (HFuEF) with regard to re-hospitalization due to congestive HF (CHF), adequate electric therapies (AETs) and mortality compared to...

Cite
Zeller J, Hubauer U, Schober A, et al. Heart failure with recovered ejection fraction (HFrecEF): A new entity with improved cardiac outcome. Pacing Clin Electrophysiol. 2021;44(12):2015-2023doi: 10.1111/pace.14391.
Zeller, J., Hubauer, U., Schober, A., Schober, A., Keyser, A., Fredersdorf, S., Uecer, E., Maier, L. S., & Jungbauer, C. (2021). Heart failure with recovered ejection fraction (HFrecEF): A new entity with improved cardiac outcome. Pacing and clinical electrophysiology : PACE, 44(12), 2015-2023. https://doi.org/10.1111/pace.14391
Zeller, Judith, et al. "Heart failure with recovered ejection fraction (HFrecEF): A new entity with improved cardiac outcome." Pacing and clinical electrophysiology : PACE vol. 44,12 (2021): 2015-2023. doi: https://doi.org/10.1111/pace.14391
Zeller J, Hubauer U, Schober A, Schober A, Keyser A, Fredersdorf S, Uecer E, Maier LS, Jungbauer C. Heart failure with recovered ejection fraction (HFrecEF): A new entity with improved cardiac outcome. Pacing Clin Electrophysiol. 2021 Dec;44(12):2015-2023. doi: 10.1111/pace.14391. Epub 2021 Nov 04. PMID: 34687476.
Copy Download .nbib Format: NLM
Regioselectivity of Cobalamin-Dependent Methyltransferase Can Be Tuned by Reaction Conditions and Substrate.

ChemCatChem

Pompei S, Grimm C, Farnberger JE, Schober L, Kroutil W.
PMID: 33442427
ChemCatChem. 2020 Dec 04;12(23):5977-5983. doi: 10.1002/cctc.202001296. Epub 2020 Oct 01.

Regioselective reactions represent a significant challenge for organic chemistry. Here the regioselective methylation of a single hydroxy group of 4-substituted catechols was investigated employing the cobalamin-dependent methyltransferase from

Cite
Pompei S, Grimm C, Farnberger JE, et al. Regioselectivity of Cobalamin-Dependent Methyltransferase Can Be Tuned by Reaction Conditions and Substrate. ChemCatChem. 2020;12(23):5977-5983doi: 10.1002/cctc.202001296.
Pompei, S., Grimm, C., Farnberger, J. E., Schober, L., & Kroutil, W. (2020). Regioselectivity of Cobalamin-Dependent Methyltransferase Can Be Tuned by Reaction Conditions and Substrate. ChemCatChem, 12(23), 5977-5983. https://doi.org/10.1002/cctc.202001296
Pompei, Simona, et al. "Regioselectivity of Cobalamin-Dependent Methyltransferase Can Be Tuned by Reaction Conditions and Substrate." ChemCatChem vol. 12,23 (2020): 5977-5983. doi: https://doi.org/10.1002/cctc.202001296
Pompei S, Grimm C, Farnberger JE, Schober L, Kroutil W. Regioselectivity of Cobalamin-Dependent Methyltransferase Can Be Tuned by Reaction Conditions and Substrate. ChemCatChem. 2020 Dec 04;12(23):5977-5983. doi: 10.1002/cctc.202001296. Epub 2020 Oct 01. PMID: 33442427; PMCID: PMC7783988.
Copy Download .nbib Format: NLM
Paternal Leave and Father-Infant Bonding: Findings From the Population-Based Cohort Study DREAM.

Frontiers in psychology

Schaber R, Kopp M, Zähringer A, Mack JT, Kress V, Garthus-Niegel S.
PMID: 34149562
Front Psychol. 2021 Jun 04;12:668028. doi: 10.3389/fpsyg.2021.668028. eCollection 2021.

No abstract available.

Cite
Schaber R, Kopp M, Zähringer A, et al. Paternal Leave and Father-Infant Bonding: Findings From the Population-Based Cohort Study DREAM. Front Psychol. 2021;12:668028doi: 10.3389/fpsyg.2021.668028.
Schaber, R., Kopp, M., Zähringer, A., Mack, J. T., Kress, V., & Garthus-Niegel, S. (2021). Paternal Leave and Father-Infant Bonding: Findings From the Population-Based Cohort Study DREAM. Frontiers in psychology, 12668028. https://doi.org/10.3389/fpsyg.2021.668028
Schaber, Ronja, et al. "Paternal Leave and Father-Infant Bonding: Findings From the Population-Based Cohort Study DREAM." Frontiers in psychology vol. 12 (2021): 668028. doi: https://doi.org/10.3389/fpsyg.2021.668028
Schaber R, Kopp M, Zähringer A, Mack JT, Kress V, Garthus-Niegel S. Paternal Leave and Father-Infant Bonding: Findings From the Population-Based Cohort Study DREAM. Front Psychol. 2021 Jun 04;12:668028. doi: 10.3389/fpsyg.2021.668028. eCollection 2021. PMID: 34149562; PMCID: PMC8212974.
Copy Download .nbib Format: NLM
Bcr-TMP, a Novel Nanomolar-Active Compound That Exhibits Both MYB- and Microtubule-Inhibitory Activity.

Cancers

Yusenko MV, Biyanee A, Frank D, Köhler LHF, Andersson MK, Khandanpour C, Schobert R, Stenman G, Biersack B, Klempnauer KH.
PMID: 35008207
Cancers (Basel). 2021 Dec 23;14(1). doi: 10.3390/cancers14010043.

Studies of the role of MYB in human malignancies have highlighted MYB as a potential drug target for acute myeloid leukemia (AML) and adenoid cystic carcinoma (ACC). Here, we present the initial characterization of 2-amino-4-(3,4,5-trimethoxyphenyl)-4

Cite
Yusenko MV, Biyanee A, Frank D, et al. Bcr-TMP, a Novel Nanomolar-Active Compound That Exhibits Both MYB- and Microtubule-Inhibitory Activity. Cancers (Basel). 2021;14(1)doi: 10.3390/cancers14010043.
Yusenko, M. V., Biyanee, A., Frank, D., Köhler, L. H. F., Andersson, M. K., Khandanpour, C., Schobert, R., Stenman, G., Biersack, B., & Klempnauer, K. H. (2021). Bcr-TMP, a Novel Nanomolar-Active Compound That Exhibits Both MYB- and Microtubule-Inhibitory Activity. Cancers, 14(1), . https://doi.org/10.3390/cancers14010043
Yusenko, Maria V, et al. "Bcr-TMP, a Novel Nanomolar-Active Compound That Exhibits Both MYB- and Microtubule-Inhibitory Activity." Cancers vol. 14,1 (2021). doi: https://doi.org/10.3390/cancers14010043
Yusenko MV, Biyanee A, Frank D, Köhler LHF, Andersson MK, Khandanpour C, Schobert R, Stenman G, Biersack B, Klempnauer KH. Bcr-TMP, a Novel Nanomolar-Active Compound That Exhibits Both MYB- and Microtubule-Inhibitory Activity. Cancers (Basel). 2021 Dec 23;14(1). doi: 10.3390/cancers14010043. PMID: 35008207; PMCID: PMC8750090.
Copy Download .nbib Format: NLM
COVID-19 in Patients Receiving CD20-depleting Immunochemotherapy for B-cell Lymphoma.

HemaSphere

Gaitzsch E, Passerini V, Khatamzas E, Strobl CD, Muenchhoff M, Scherer C, Osterman A, Heide M, Reischer A, Subklewe M, Leutbecher A, Tast B, Ruhle A, Weiglein T, Stecher SS, Stemmler HJ, Dreyling M, Girl P, Georgi E, Wölfel R, Mateyka L, D'Ippolito E, Schober K, Busch DH, Kager J, Spinner CD, Treiber M, Rasch S, Lahmer T, Iakoubov R, Schneider J, Protzer U, Winter C, Ruland J, Quante M, Keppler OT, von Bergwelt-Baildon M, Hellmuth J, Weigert O.
PMID: 34235400
Hemasphere. 2021 Jun 28;5(7):e603. doi: 10.1097/HS9.0000000000000603. eCollection 2021 Jul.

The clinical and immunological impact of B-cell depletion in the context of coronavirus disease 2019 (COVID-19) is unclear. We conducted a prospectively planned analysis of COVID-19 in patients who received B-cell depleting anti-CD20 antibodies and chemotherapy for B-cell lymphomas....

Cite
Gaitzsch E, Passerini V, Khatamzas E, et al. COVID-19 in Patients Receiving CD20-depleting Immunochemotherapy for B-cell Lymphoma. Hemasphere. 2021;5(7):e603doi: 10.1097/HS9.0000000000000603.
Gaitzsch, E., Passerini, V., Khatamzas, E., Strobl, C. D., Muenchhoff, M., Scherer, C., Osterman, A., Heide, M., Reischer, A., Subklewe, M., Leutbecher, A., Tast, B., Ruhle, A., Weiglein, T., Stecher, S. S., Stemmler, H. J., Dreyling, M., Girl, P., Georgi, E., Wölfel, R., Mateyka, L., D'Ippolito, E., Schober, K., Busch, D. H., Kager, J., Spinner, C. D., Treiber, M., Rasch, S., Lahmer, T., Iakoubov, R., Schneider, J., Protzer, U., Winter, C., Ruland, J., Quante, M., Keppler, O. T., von Bergwelt-Baildon, M., Hellmuth, J., & Weigert, O. (2021). COVID-19 in Patients Receiving CD20-depleting Immunochemotherapy for B-cell Lymphoma. HemaSphere, 5(7), e603. https://doi.org/10.1097/HS9.0000000000000603
Gaitzsch, Erik, et al. "COVID-19 in Patients Receiving CD20-depleting Immunochemotherapy for B-cell Lymphoma." HemaSphere vol. 5,7 (2021): e603. doi: https://doi.org/10.1097/HS9.0000000000000603
Gaitzsch E, Passerini V, Khatamzas E, Strobl CD, Muenchhoff M, Scherer C, Osterman A, Heide M, Reischer A, Subklewe M, Leutbecher A, Tast B, Ruhle A, Weiglein T, Stecher SS, Stemmler HJ, Dreyling M, Girl P, Georgi E, Wölfel R, Mateyka L, D'Ippolito E, Schober K, Busch DH, Kager J, Spinner CD, Treiber M, Rasch S, Lahmer T, Iakoubov R, Schneider J, Protzer U, Winter C, Ruland J, Quante M, Keppler OT, von Bergwelt-Baildon M, Hellmuth J, Weigert O. COVID-19 in Patients Receiving CD20-depleting Immunochemotherapy for B-cell Lymphoma. Hemasphere. 2021 Jun 28;5(7):e603. doi: 10.1097/HS9.0000000000000603. eCollection 2021 Jul. PMID: 34235400; PMCID: PMC8240782.
Copy Download .nbib Format: NLM
MicroRNA-21 Controls Circadian Regulation of Apoptosis in Atherosclerotic Lesions.

Circulation

Schober A, Blay RM, Saboor Maleki S, Zahedi F, Winklmaier AE, Kakar MY, Baatsch IM, Zhu M, Geißler C, Fusco AE, Eberlein A, Li N, Megens RTA, Banafsche R, Kumbrink J, Weber C, Nazari-Jahantigh M.
PMID: 34233454
Circulation. 2021 Sep 28;144(13):1059-1073. doi: 10.1161/CIRCULATIONAHA.120.051614. Epub 2021 Jul 08.

BACKGROUND: The necrotic core partly formed by ineffective efferocytosis increases the risk of an atherosclerotic plaque rupture. Microribonucleic acids contribute to necrotic core formation by regulating efferocytosis and macrophage apoptosis. Atherosclerotic plaque rupture occurs at increased frequency in the...

Cite
Schober A, Blay RM, Saboor Maleki S, et al. MicroRNA-21 Controls Circadian Regulation of Apoptosis in Atherosclerotic Lesions. Circulation. 2021;144(13):1059-1073doi: 10.1161/CIRCULATIONAHA.120.051614.
Schober, A., Blay, R. M., Saboor Maleki, S., Zahedi, F., Winklmaier, A. E., Kakar, M. Y., Baatsch, I. M., Zhu, M., Geißler, C., Fusco, A. E., Eberlein, A., Li, N., Megens, R. T. A., Banafsche, R., Kumbrink, J., Weber, C., & Nazari-Jahantigh, M. (2021). MicroRNA-21 Controls Circadian Regulation of Apoptosis in Atherosclerotic Lesions. Circulation, 144(13), 1059-1073. https://doi.org/10.1161/CIRCULATIONAHA.120.051614
Schober, Andreas, et al. "MicroRNA-21 Controls Circadian Regulation of Apoptosis in Atherosclerotic Lesions." Circulation vol. 144,13 (2021): 1059-1073. doi: https://doi.org/10.1161/CIRCULATIONAHA.120.051614
Schober A, Blay RM, Saboor Maleki S, Zahedi F, Winklmaier AE, Kakar MY, Baatsch IM, Zhu M, Geißler C, Fusco AE, Eberlein A, Li N, Megens RTA, Banafsche R, Kumbrink J, Weber C, Nazari-Jahantigh M. MicroRNA-21 Controls Circadian Regulation of Apoptosis in Atherosclerotic Lesions. Circulation. 2021 Sep 28;144(13):1059-1073. doi: 10.1161/CIRCULATIONAHA.120.051614. Epub 2021 Jul 08. PMID: 34233454.
Copy Download .nbib Format: NLM
Showing 397 to 404 of 404 entries